Drug
Repotrectinib clinical trials
Also written TPX-0005 and BMS-986472.
- studies test it
- 13
- open now
- 6
- in phase 3
- 1
- first study started
- 2017
Keep track of what changes. Save the repotrectinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
Studies by the year they started
13 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 6
- Phase 3
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Turning Point Therapeutics, Inc. (5) · Bristol-Myers Squibb (4) · MedSIR (1) · Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer (1) · Memorial Sloan Kettering Cancer Center (1) · Instituto Oncológico Dr Rosell (1)
Often tested with
Tested in the same studies.
Voriconazole (1) · Quinidine (1) · Osimertinib (1) · Metformin (1) · Digoxin (1)
Studies
Open first, then newest update. How each study uses repotrectinib is read from its arms, and is right about nine times in ten.
Testing it · 13
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingPhase 1/2Turning Point Therapeutics, Inc.NCT04094610Written as Oral repotrectinib (TPX-0005)
- Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain MetastasisRecruitingPhase 2MedSIRNCT06315010Written as Repotrectinib
- Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLCRecruitingPhase 2Centre Hospitalier Intercommunal de Toulon La Seyne sur MerNCT06552234Written as Repotrectinib
- A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor CancerRecruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT05004116Written as Repotrectinib
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingPhase 1/2Turning Point Therapeutics, Inc.NCT03093116Written as Oral repotrectinib (TPX-0005)
- Phase I Study of Repotrectinib and Osimertinib in NSCLC PatientsRecruitingPhase 1Instituto Oncológico Dr RosellNCT04772235Written as Repotrectinib
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Active, not recruitingPhase 3Bristol-Myers SquibbNCT06140836Written as Repotrectinib
- Study to Evaluate the Effect of Repotrectinib on the Drug Levels of Transporter and CYP P450 Probe Substrates in Healthy Adult ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT07223671Written as Repotrectinib
- A Study to Assess the Drug Levels of Repotrectinib in Healthy Participants and Participants With Moderate and Severe Hepatic ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT06352528Written as Repotrectinib
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT06493409Written as Repotrectinib
- A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsWithdrawnPhase 1Turning Point Therapeutics, Inc.NCT05828303Written as TPX-0005
- A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid TumorsTerminatedPhase 1/2Turning Point Therapeutics, Inc.NCT05071183Written as TPX-0005
- A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer PatientsWithdrawnPhase 1Turning Point Therapeutics, Inc.NCT05828277Written as repotrectinib (TPX-0005)
Given in every arm · 1 — repotrectinib is usual care beside what is tested
Codes
What other systems call repotrectinib · ClinicalTrials.gg INT001361
- MeSH (NLM) C000708510repotrectinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 08O3FQ4UNPREPOTRECTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q123499554repotrectinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C133821RepotrectinibOne source FDA
- DrugBank DB16826One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000708510 | repotrectinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 08O3FQ4UNP | REPOTRECTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q123499554 | repotrectinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C133821 | Repotrectinib | One source FDA |
| DrugBank | DB16826 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.